AstraZeneca’s IMFINZI ® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve ...

US FDA approves AstraZeneca’s Imfinzi for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer: Cambridge, UK Saturday, May 30, 2026, 13:00 Hrs [IST] AstraZene ...

ImmunityBio targets the BCG shortage with new supply deals and label expansion efforts that could strengthen Anktiva demand in bladder cancer.

Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter AstraZeneca ( (GB:AZN)) has issued an update. AstraZeneca has secured U.S. FDA approval ...

Patients and urologists are not always aligned on what the treatment experience will be li ...

Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.

Let’s strive for a tobacco-free world Althoughthere is a statutory warning on every packet that ‘cigarette smoking is ...

AstraZeneca says its drug Imfinzi is approved in the US as the first and only immunotherapy combination for patients with BCG-naive, high-risk non-muscle-invasive bladder cancer. The Cambridge, ...

Faced with a future of evaporating Xtandi sales, Astellas has set out ambitions to license fresh assets while also continuing ...

During the quarter ended March 31, 2026, Baron Health Care Fund® (the Fund) declined 6.97% (Institutional Shares), compared ...

EU recommends approval of AstraZeneca & Daiichi Sankyo’s Enhertu for patients with previously treated HER2-positive metastatic solid tumours: Cambridge, UK Monday, May 25, 2026, ...

LOS ANGELES, CA– In a groundbreaking achievement set to reshape the future of transplant medicine, Dr. Inderbir S. Gill has led the world’s first successful bladder transplant in a human being. The ...